Clinical trials: Squamous-Cell Lung Cancer
Non-small-cell Lung Cancer
Stereotactic Body Radiotherapy (SBRT) Versus Stereotactic Body Proton Therapy (SBPT)
The goal of this clinical research study is to compare 2 types of radiotherapy, stereotactic body photon radiotherapy (SBRT) and stereotactic body proton radiotherapy (SBPT).
- Trial name
- NCT01511081
- Testing
- SBRT (stereotactic body radiotherapy), SBPT (stereotactic body proton therapy)
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- M.D. Anderson Cancer Center
Non-Small Cell Lung Cancer, Colorectal Cancer
A Study of SOT101 in Combination With Pembrolizumab to Evaluate the Efficacy and Safety in Patients With Selected Advanced Solid Tumors
The primary objective of the study is to estimate the antitumor efficacy of nanrilkefusp alfa in combination with pembrolizumab in selected tumors.
- Conditions
- Non-Small Cell Lung Cancer, Colorectal Cancer, Cutaneous Squamous Cell Carcinoma, Hepatocellular Carcinoma
- Trial name
- NCT05256381
- Testing
- Nanrilkefusp Alfa, Pembrolizumab
- Where
- 54 sites in United States, Belgium and 7 more
- Volunteers
- 166 people
- Sponsor
- SOTIO Biotech AG
Non-small Cell Lung Cancer, Squamous Cell Carcinoma of the Head and Neck
Priming Immunotherapy in Advanced Disease With Radiation
This study proposes to treat metastatic non-small cell lung cancer (NSCLC) and head/neck squamous cell cancer (HNSCC) patients who are already initiating an immune checkpoint inhibitor (such as Nivolumab, Atezolizumab or…
- Trial name
- NCT03313804
- Testing
- Immune checkpoint inhibitor, Radiation Therapy
- Where
- United States
- Volunteers
- 76 people
- Sponsor
- John L. Villano, MD, PhD
Gastric Adenocarcinoma, Esophageal Cancer
Study of Sacituzumab Govitecan-hziy (IMMU-132) in Adults With Epithelial Cancer
The primary objective in Phase I is to evaluate the safety and tolerability of sacituzumab govitecan-hziy (SG) as a single agent administered in 21-day treatment cycles in previously treated participants with advanced epithelial…
- Conditions
- Gastric Adenocarcinoma, Esophageal Cancer, Hepatocellular Carcinoma, Non-small Cell Lung Cancer
- Trial name
- NCT01631552
- Testing
- Sacituzumab Govitecan-hziy (SG)
- Where
- 12 sites in United States
- Volunteers
- 515 people
- Sponsor
- Gilead Sciences
Triple-Negative Breast Neoplasms, Carcinoma, Non-Small-Cell Lung
A Study of TAK-659 in Combination With Nivolumab in Participants With Advanced Solid Tumors
The purpose of this study is to evaluate the maximum tolerated dose (MTD) or recommended Phase 2 dose (RP2D), safety and efficacy of TAK-659 in combination with nivolumab in participants with advanced solid tumors.
- Conditions
- Triple-Negative Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Head and Neck Carcinoma, Squamous Cell, Advanced Solid Tumors
- Trial name
- NCT02834247
- Testing
- TAK-659, Nivolumab
- Where
- 22 sites in United States, Italy and 2 more
- Volunteers
- 41 people
- Sponsor
- Calithera Biosciences, Inc
Carcinoma, Non-Small Cell Lung Cancer (NSCLC)
A Study of Nab-Paclitaxel and Carboplatin Plus Necitumumab (LY3012211) in Participants With Stage IV Squamous NSCLC
The purpose of the study is to determine if nab-paclitaxel and carboplatin chemotherapy plus necitumumab is effective and safe in participants with stage IV squamous non-small cell lung cancer.
- Trial name
- NCT02392507
- Testing
- Necitumumab, Nab-Paclitaxel, Carboplatin
- Where
- United States
- Volunteers
- 54 people
- Sponsor
- Eli Lilly and Company
Squamous Cell Carcinoma
Selinexor Treatment of Advanced Relapsed/Refractory Squamous Cell Carcinomas
Open-label, multi-center, single-arm, Phase 2 study of oral selinexor in patients with SCC of the head and neck (HN-SCC; Cohort 1), lung (L-SCC; Cohort 2), or esophagus (E-SCC; Cohort 3) who have relapsed or have metastasis…
- Trial name
- STARRS (NCT02213133)
- Testing
- Selinexor (KPT-330)
- Where
- 18 sites in United States, Canada
- Volunteers
- 45 people
- Sponsor
- Karyopharm Therapeutics Inc
Non-small Cell Lung Cancer
A Study of Carboplatin-Paclitaxel/Nab-Paclitaxel Chemotherapy With or Without Pembrolizumab (MK-3475) in Adults With First Line Metastatic Squamous Non-small Cell Lung Cancer (MK-3475-407/KEYNOTE-407)
This is a study of carboplatin and paclitaxel or nano particle albumin-bound paclitaxel (nab-paclitaxel) with or without pembrolizumab (MK-3475, KEYTRUDA®) in adults with first line metastatic squamous non-small cell lung cancer…
- Trial name
- NCT02775435
- Testing
- Pembrolizumab, Paclitaxel, Nab-paclitaxel
- Volunteers
- 559 people
- Sponsor
- Merck Sharp & Dohme LLC
Lung Cancer
Chemotherapy and Radiation Therapy With or Without Panitumumab in Treating Patients With Stage IIIA Non-Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy (CT), such as paclitaxel and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00979212
- Testing
- panitumumab, carboplatin, paclitaxel
- Where
- 31 sites in United States
- Volunteers
- 71 people
- Sponsor
- Radiation Therapy Oncology Group
Non-small Cell Lung Cancer
REGN2810 (Anti-PD-1 Antibody), Platinum-based Doublet Chemotherapy, and Ipilimumab (Anti-CTLA-4 Antibody) Versus Pembrolizumab Monotherapy in Patients With Lung Cancer
The primary objective of the study is to compare the progression-free survival (PFS) of REGN2810 (cemiplimab) plus ipilimumab combination therapy (hereinafter referred to as REGN2810/ipi) and REGN2810 plus 2 cycles only of…
- Trial name
- NCT03515629
- Testing
- REGN2810/ipi, REGN2810/chemo/ipi, Pembrolizumab
- Where
- 3 sites in United States, Italy and 1 more
- Volunteers
- 5 people
- Sponsor
- Regeneron Pharmaceuticals
Non-Squamous Non-Small Cell Lung Cancer
A Study of Metronidazole Cream in the Prevention and Treatment of Tarceva (Erlotinib)-Associated Rash
This study will evaluate the efficacy and safety of metronidazole actavis 1 percent (%) topical cream in the prevention and treatment of rash associated with Tarceva treatment, in participants with non-small cell lung cancer.
- Trial name
- MATER (NCT00642473)
- Testing
- Erlotinib, Metronidazole Actavis, Non-active Moisturizing Cream
- Where
- 6 sites in Sweden
- Volunteers
- 34 people
- Sponsor
- Hoffmann-La Roche
Small Cell Lung Cancer, Non-small Cell Lung Cancer, Squamous
A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors
This trial will study ladiratuzumab vedotin (LV) alone and with pembrolizumab to find out if it works to treat different types of solid tumors. It will also find out what side effects may occur.
- Conditions
- Small Cell Lung Cancer, Non-small Cell Lung Cancer, Squamous, Non-small Cell Lung Cancer, Non-squamous, Head and Neck Squamous Cell Carcinoma
- Trial name
- NCT04032704
- Testing
- ladiratuzumab vedotin, pembrolizumab
- Where
- 66 sites in United States, Australia and 4 more
- Volunteers
- 205 people
- Sponsor
- Seagen Inc.
Lung Adenocarcinoma, Lung Adenocarcinoma, Mixed Subtype
Veliparib With or Without Radiation Therapy, Carboplatin, and Paclitaxel in Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery
This phase I/II partially randomized trial studies the side effects and best dose of veliparib when given together with radiation therapy, carboplatin, and paclitaxel and to see how well it works in treating patients with stage…
- Conditions
- Lung Adenocarcinoma, Lung Adenocarcinoma, Mixed Subtype, Lung Large Cell Carcinoma, Lung Squamous Cell Carcinoma
- Trial name
- NCT01386385
- Testing
- 3-Dimensional Conformal Radiation Therapy, Carboplatin, Laboratory Biomarker Analysis
- Where
- 232 sites in United States
- Volunteers
- 53 people
- Sponsor
- National Cancer Institute (NCI)
FGFR1 Gene Amplification, FGFR1 Gene Mutation
Lung-MAP: AZD4547 as Second-Line Therapy in Treating FGFR Positive Patients With Recurrent Stage IV Squamous Cell Lung Cancer
This phase II/III trial studies how well FGFR inhibitor AZD4547 (AZD4547) works in treating patients with stage IV squamous cell lung cancer that has come back after previous treatment.
- Conditions
- FGFR1 Gene Amplification, FGFR1 Gene Mutation, FGFR2 Gene Amplification, FGFR2 Gene Mutation
- Trial name
- NCT02965378
- Testing
- Docetaxel, FGFR Inhibitor AZD4547, Laboratory Biomarker Analysis
- Where
- 1,084 sites in United States, Canada
- Volunteers
- 43 people
- Sponsor
- SWOG Cancer Research Network
Locally Advanced, Unresectable, or Metastatic Nonsmall Cell Lung Cancer (NSCLC), Nonsmall Cell Lung Cancer, Stage IIIB
Ociperlimab With Tislelizumab and Chemotherapy in Participants With Untreated Metastatic Non-Small Cell Lung Cancer
This study aimed to evaluate the safety and effectiveness of ociperlimab combined with tislelizumab and chemotherapy, compared to tislelizumab and chemotherapy alone, in participants with non-small cell lung cancer (NSCLC) that…
- Conditions
- Locally Advanced, Unresectable, or Metastatic Nonsmall Cell Lung Cancer (NSCLC), Nonsmall Cell Lung Cancer, Stage IIIB, Nonsmall Cell Lung Cancer, Stage IV
- Trial name
- NCT05014815
- Testing
- Ociperlimab, Tislelizumab, Carboplatin
- Where
- 64 sites in United States, Australia and 6 more
- Volunteers
- 272 people
- Sponsor
- BeiGene
Non-Small Cell Lung Cancer, Head and Neck Cancer
Ponatinib for Squamous Cell Lung and Head and Neck Cancers
This research study is a Phase II clinical trial, which tests the safety and effectiveness of an investigational drug to learn whether the drug works in treating a specific cancer.
- Trial name
- NCT01761747
- Testing
- ponatinib
- Where
- 4 sites in United States
- Volunteers
- 3 people
- Sponsor
- Dana-Farber Cancer Institute
Pancreatic Cancer, Hepatocellular Cancer
A Study of TAK-500 With or Without Pembrolizumab in Adults With Select Locally Advanced or Metastatic Solid Tumors
This study is about TAK-500, given either alone or with pembrolizumab, in adults with select locally advanced or metastatic solid tumors.
- Conditions
- Pancreatic Cancer, Hepatocellular Cancer, Mesothelioma, Breast Cancer
- Trial name
- NCT05070247
- Testing
- TAK-500, Pembrolizumab, Tocilizumab
- Where
- 12 sites in United States
- Volunteers
- 61 people
- Sponsor
- Takeda
Non-squamous, Non-Small Cell Lung Cancer
Non-interventional Study for Real-world Data of Afatinib Treatment in First-line Setting and of Subsequent Therapies for Patients With Advanced Epidermal Growth Factor Receptor (EGFR) Mutation-positive Lung Adenocarcinoma
The primary objective is to confirm Time on Treatment (TOT) related to afatinib treatment as first-line therapy in patients with Epidermal Growth Factor Receptor (EGFR) mutation-positive Non-Small Cell Lung Cancer (NSCLC).
- Trial name
- NCT04795245
- Testing
- afatinib
- Where
- Japan
- Volunteers
- 805 people
- Sponsor
- Boehringer Ingelheim
Lung Neoplasms
Efficacy and Safety Evaluation of Sintilimab in Patients With Advanced or Metastatic Non-squamous NSCLC
Efficacy and Safety Evaluation of IBI308 in Patients with advanced or metastatic Non-squamous NSCLC
- Trial name
- NCT03607539
- Testing
- Sintilimab, Pemetrexed, Platinum
- Where
- China
- Volunteers
- 397 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Non-Squamous Non-Small Cell Lung Cancer
A Study of Tarceva (Erlotinib) as First Line Therapy in Participants With Non-Small Cell Lung Cancer Harbouring Epidermal Growth Factor Receptor (EGFR) Mutations
This open-label, single arm study will evaluate the safety and efficacy of Tarceva (erlotinib) as first-line therapy in participants with stage IV or recurrent non-small cell lung cancer who harbour epidermal growth factor…
- Trial name
- NCT01310036
- Testing
- Erlotinib
- Where
- 22 sites in Hong Kong, South Korea and 2 more
- Volunteers
- 208 people
- Sponsor
- Hoffmann-La Roche